news

Potential therapeutic target identified for stomach cancer

A team has shown that removing the inflammatory signalling protein TNF in a laboratory model prevented stomach cancers from becoming severe.

Stomach cancer

Researchers have identified a key molecular regulator involved in the progression and spread of stomach cancer, suggesting a potential new approach to treat this devastating disease. The study was conducted at the Water and Eliza Hall Institute (WEHI), Australia. 

The team discovered that removing the inflammatory signalling protein TNF in a laboratory model prevented early stage stomach cancers from progressing to a more severe stage that, in humans, is much harder to treat. This discovery suggests that stomach cancers may respond to medicines that inhibit TNF. 

“Human stomach cancer can be caused by prolonged inflammation and our model of stomach cancer, that is driven by the absence of the protein NF-KB1, accurately reflects the sequential changes seen in human stomach cancer as it progresses from an early, inflammatory stage. We discovered that invasive stomach cancers contain high levels of various factors involved in inflammation, including four soluble proteins called cytokines,” said lead researcher Dr Lorraine O’Reilly. “By removing each of the four cytokines that were elevated in our model, we could assess how important each one was. This revealed that the cytokine TNF was required for the progression of stomach cancer.”

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

“Many therapies have shown great promise in treating inflammatory diseases by targeting specific cytokines,” lead researcher Dr Tracy Putoczki said. “Excitingly, there are already medicines in clinical use that block TNF, most notably for the treatment of rheumatoid arthritis. Our research suggests these therapies could be an effective and safe way to prevent the progression of stomach cancer to more severe, invasive forms. This is an area we are looking at in more detail.”

The research was published in the journal Gastroenterology.

Leave a Reply

Your email address will not be published. Required fields are marked *